Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD4 CAR T Cells for Relapsed/Refractory T Cell Malignancies
NCT04162340Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in T-cell lymphoma, sponsored by iCell Gene Therapeutics. Primary endpoint: Number of adverse events after CD4 CAR T cells cell infusion at 28 days. Status: unknown.
02
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT04162340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162340.